Powered by the Scientific Committee as its academic engine and driven by the bidirectional data feedback between IND trials and IITs (Investigator-Initiated Trials), Harbour Medical continuously drives the efficient translation of innovative therapies from laboratory to clinic.
Harbour Medical is the core business platform of Harbour BioMed dedicated to clinical development and medical services, committed to providing end-to-end solutions for global innovative therapies — from early clinical validation through post-marketing studies.
The platform simultaneously undertakes clinical trial programs across Harbour BioMed's full internal product pipeline and provides clinical development services for external partners, encompassing co-development, strategic partnerships, and clinical CRO engagement models.
Powered by the Scientific Committee as its academic engine and driven by the bidirectional data feedback between IITs (Investigator-Initiated Trials) and IND trials, Harbour Medical continuously drives the efficient translation of innovative therapies from laboratory to clinic.
Leveraging full-lifecycle clinical development capabilities, the platform efficiently advances internal pipeline candidates from First-in-Human (FIH) through regulatory approval; concurrently, it provides global partners with co-development, end-to-end services, and strategic partnerships — combining professional operations with shared risk to accelerate patient access to innovative therapies.
Harbour Medical undertakes comprehensive clinical trial design and execution across Harbour BioMed's internal product pipeline, covering the full lifecycle from First-in-Human (FIH) studies to Pivotal Registration studies, ensuring efficient and compliant advancement toward regulatory submission.
Providing professional clinical development services for global biopharmaceutical partners, including but not limited to:
Grounded in scientific evidence to ensure rigorous trial design, reliable data, and clinically meaningful conclusions
Coordinated review by medical, statistical, pharmacological, and regulatory experts across the full trial lifecycle
Tracking frontier scientific advances to drive the application of adaptive designs, real-world evidence, and other innovative methodologies
A bidirectional drive between IND trials and IITs (Investigator-Initiated Trials), accelerating the overall advancement of the product pipeline through scientific insights:
Leveraging clinical data and experience from IITs to optimize IND trial design, patient stratification strategies, and endpoint selection, reducing development risk and improving success rates
Rapidly and cost-effectively exploring new indications, combination regimens, and biomarker hypotheses through investigator-initiated trials, providing reference clinical evidence for subsequent IND programs
Corresponding capabilities span multiple stages from strategy development to regulatory submission, with efficiency gains stacking cumulatively to 50% overall.
Key deliverables routinely achieve 2–4× acceleration (e.g., Protocol 8→2 weeks, TFL 8→2 weeks, CSR 1 month→1 week), directly translating into earlier data readouts and accelerated time-to-market.
Site selection accuracy +30–50%, compliance risk −30%, project delays −30–50%: efficiency and quality improve in tandem.
ICSR entry and document quality checks at minute-level or even second-level granularity, transforming reactive remediation into proactive, real-time control.
Digital twins advance "cost-efficiency optimization" to "failure rate reduction;" virtual synthetic control arms provide pathways unavailable through traditional methods in rare disease, pediatric, and ethically constrained settings.
